Becton, Dickinson and Company $BDX Shares Acquired by Martingale Asset Management L P

Martingale Asset Management L P increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 105.5% in the first quarter, Holdings Channel reports. The firm owned 74,575 shares of the medical instruments supplier’s stock after buying an additional 38,292 shares during the quarter. Martingale Asset Management L P’s holdings in Becton, Dickinson and Company were worth $17,082,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after acquiring an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in shares of Becton, Dickinson and Company by 3.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock worth $2,880,510,000 after purchasing an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after purchasing an additional 667,957 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Becton, Dickinson and Company by 7.6% in the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock worth $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Kovitz Investment Group Partners LLC raised its holdings in Becton, Dickinson and Company by 392.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier’s stock worth $775,139,000 after purchasing an additional 2,722,829 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Up 0.6%

BDX opened at $199.2480 on Thursday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The business has a 50-day moving average of $179.66 and a two-hundred day moving average of $196.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock has a market capitalization of $57.11 billion, a price-to-earnings ratio of 35.84, a price-to-earnings-growth ratio of 1.48 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the previous year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 863 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the sale, the director directly owned 23,143 shares of the company’s stock, valued at $4,450,398.90. This trade represents a 3.59% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,214 shares of company stock worth $579,206. 0.36% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

BDX has been the topic of several recent analyst reports. Piper Sandler reiterated a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Barclays reduced their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research note on Tuesday, June 3rd. Finally, Raymond James Financial lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.